Am J Cancer Res 2012;2(3):298-308
Original Article
KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer
Elisa Caiola, Eliana Rulli, Robert Fruscio, Alessandro Buda, Massimo Broggini, Mirko Marabese
Laboratory of Molecular Pharmacology; Laboratory of Clinical Trials, Department of Oncology, Istituto di Ricerche
Farmacologiche “Mario Negri”, Milan, Italy; Clinic of Obstetrics and Gynecology, University of Milan-Bicocca, San Gerardo
Hospital, Monza, Italy
Received March 27, 2012; accepted April 17, 2012; Epub April 21, 2012; Published May 15, 2012
Abstract: Epithelial ovarian cancer is a malignancy with high rate of death due to an advanced disease at diagnosis and
frequent relapse after chemotherapy. Nowadays, there is a lack of knowledge for clear risk factors and predictive and/or
prognostic genetic markers although genomic alterations such as mutations in p53, PTEN, BRCA1/BRCA2, HER2, KRAS and
PI3K genes have been associated to this pathology. A genomic variant in the 3’ untraslated region of cancer related gene KRAS,
is able to disrupt the let-7 miRNA binding site. The SNP, commonly named KRAS-LCS6, determines the substitution of the more
abundant T-allele to a G-allele which was observed to increase the KRAS expression and in turn to activate the downstream
pathway at higher levels if compared to the T-allele. In this study we assessed the role of the KRAS-LCS6 polymorphism
(rs61764370) in 97 early (stages I and II) and 232 advanced (stages III and IV) ovarian cancer patients in order to associate this
SNP to any physiopathological characteristic of the patients cohort, including progression free survival and overall survival, with a
follow up data longer than ten years. Our data indicate that KRAS-LCS6 polymorphism is not relevant in ovarian cancer, in fact, in
our cohort of patients, is not associated to any outcome or physiopathological characteristic. (AJCR00000112).
Keywords: KRAS, let-7, ovarian cancer, LCS6, miRNA, rs61764370
Address all correspondence to:
Dr. Massimo Broggini
Laboratory of Molecular Pharmacology
Department of Oncology. via La Masa 19
20156 Milan, Italy.
Fax +390239014734
E-mail: massimo.broggini@marionegri.it
Original Article
KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer
Elisa Caiola, Eliana Rulli, Robert Fruscio, Alessandro Buda, Massimo Broggini, Mirko Marabese
Laboratory of Molecular Pharmacology; Laboratory of Clinical Trials, Department of Oncology, Istituto di Ricerche
Farmacologiche “Mario Negri”, Milan, Italy; Clinic of Obstetrics and Gynecology, University of Milan-Bicocca, San Gerardo
Hospital, Monza, Italy
Received March 27, 2012; accepted April 17, 2012; Epub April 21, 2012; Published May 15, 2012
Abstract: Epithelial ovarian cancer is a malignancy with high rate of death due to an advanced disease at diagnosis and
frequent relapse after chemotherapy. Nowadays, there is a lack of knowledge for clear risk factors and predictive and/or
prognostic genetic markers although genomic alterations such as mutations in p53, PTEN, BRCA1/BRCA2, HER2, KRAS and
PI3K genes have been associated to this pathology. A genomic variant in the 3’ untraslated region of cancer related gene KRAS,
is able to disrupt the let-7 miRNA binding site. The SNP, commonly named KRAS-LCS6, determines the substitution of the more
abundant T-allele to a G-allele which was observed to increase the KRAS expression and in turn to activate the downstream
pathway at higher levels if compared to the T-allele. In this study we assessed the role of the KRAS-LCS6 polymorphism
(rs61764370) in 97 early (stages I and II) and 232 advanced (stages III and IV) ovarian cancer patients in order to associate this
SNP to any physiopathological characteristic of the patients cohort, including progression free survival and overall survival, with a
follow up data longer than ten years. Our data indicate that KRAS-LCS6 polymorphism is not relevant in ovarian cancer, in fact, in
our cohort of patients, is not associated to any outcome or physiopathological characteristic. (AJCR00000112).
Keywords: KRAS, let-7, ovarian cancer, LCS6, miRNA, rs61764370
Address all correspondence to:
Dr. Massimo Broggini
Laboratory of Molecular Pharmacology
Department of Oncology. via La Masa 19
20156 Milan, Italy.
Fax +390239014734
E-mail: massimo.broggini@marionegri.it
| AJCR Copyright © 2010-present, All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711, USA |
 | |  | |  | |  | |  | |  | |  | |  |
American Journal of Cancer Research
| ISSN: 2156-6976 |